Paul Gittens
Urology · Bala Cynwyd, PANPI 1801095369
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.2%), food and beverage and education — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 54.2% of the total. Reporting peaked in 2021 at $6,881 and has fallen 92.7% since, to $503 in 2025.
Across 87 payments — averaging $136.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$6K
- Coloplast$1K
- Medtronic$637
- Merz North America, Inc.$480
- Endo Pharmaceuticals Inc.$472
- Palette Life Sciences, Inc.$415
- plus $2K from 22 others
Across 2 payments — averaging $48,409 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Hologic Inc$97K
What the payments were for
- Consulting fees$6,42654%
- Food & beverage$5,38545%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 2 | $6,426 |
| Coloplast | 15 | $1,374 |
| Medtronic(2 entities) | 8 | $637 |
| Merz North America, Inc. | 5 | $480 |
| Endo Pharmaceuticals Inc. | 16 | $472 |
| Palette Life Sciences, Inc. | 3 | $415 |
| Boston Scientific | 5 | $320 |
| Progenics Pharmaceuticals, Inc. | 3 | $312 |
| KARL Storz Lithotripsy-america | 2 | $196 |
| Calyxo, Inc. | 2 | $152 |
| Olympus America Inc. | 2 | $145 |
| Abiomed | 1 | $145 |
| Urogen Pharma, Inc. | 1 | $142 |
| Viiv Healthcare Company | 1 | $125 |
| Antares Pharma, Inc. | 2 | $100 |
| Galderma Laboratories, L.p. | 4 | $70 |
| AbbVie(2 entities) | 2 | $47 |
| Astellas Pharma US Inc | 1 | $43 |
| Dendreon Pharmaceuticals LLC | 2 | $43 |
| AMAG Pharmaceuticals, Inc. | 2 | $40 |
| Genentech, Inc. | 1 | $34 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Halozyme Inc | 1 | $22 |
| Tolmar, Inc. | 1 | $21 |
| Clarus Therapeutics Inc. | 1 | $21 |
| Renovia Inc | 1 | $18 |
| Arteriocyte Medical Systems, Inc. | 1 | $18 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,851 in reported general payments places this provider in the 85th percentile of 596 urology providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cabergoline | 28 | $849 |
Paid to pharmacies, not to this prescriber.
Other urology in Bala Cynwyd
- Laurence BelkoffBala Cynwyd$47K
- John AndersonBethlehem$2.1M
- Demetrius BagleyPhiladelphia$739K
- Paul SieberLancaster$631K
- Daniel EunPhiladelphia$226K
- Leonard GomellaPhiladelphia$190K
- Anthony DimatteoButler$189K
- Angelo BaccalaAllentown$166K
- Phillip GinsbergPhiladelphia$145K
- Edouard TrabulsiPhiladelphia$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.